Printer Friendly

COMPANY INFORMATION
Transition Therapeutics Inc. 220-101 College St Toronto, ON M5G 1L7 Tel: (416) 260-7770 Toll-free: (877) 311-5272 Fax: (416) 260-2886 Contact Name Dr. Tony F. Cruz Industry Biotechnology		Key Executives Tony F. Cruz, CEO Elie Farah, CFO Develops products for the treatment of diabetes and Alzheimer's disease.
FP ADVISOR COVERAGE Transition Therapeutics Inc. • FP Corporate Analyzer • FP Directory of Directors • FP Corporate Surveys • Ordering FP Products		TOP INDUSTRY PLAYERS Biotechnology Company Name Revenue ($000s)  Atrium Innovations Inc. 364,726 Angiotech Pharmaceuticals, Inc. 319,113 AEterna Zentaris Inc. 72,153 QLT Inc. 48,042 GLG Life Tech Corporation 41,884 (Links are to Snapshots.)
FINANCIAL RATIOS AS OF JULY 29/10 Listed Close 52-wk High 52-wk Low IAD Latest Dividend Yield 60-mo Beta TSX/TTH NASDAQ/TTHI $3.42 $9.77 on Sept. 22/09 $2.36 on Feb. 12/10 n.a. n.a. n.a. 1.11 Avg 20-day Volume P/E 12-mo EPS EPS Date 1-yr Return 3-yr Return 5-yr Return Market Cap (000s) 3,629 n.a. $ -0.93 Mar. 31/10 -39.04% -37.03% -16.03% $79,404
ANNUAL FINANCIALS Periods ended: 12m June 30/09 12m June 30/08 12m June 30/07 $000s $000s $000s Operating revenue 2,513 1,597 684 Net income (22,374) (16,119) (16,962) Total assets 72,819 94,876 63,996 $ $ $ Earnings per share* (0.97) (0.70) (0.87) % % % Return on equity (41.59) (28.28) (39.62)   * Common
TRAILING 12-MONTH VALUES Periods ended: Mar. 31/10 Mar. 31/09 $000s $000s Operating revenue 6,348 nil Net income (21,461) (21,136) $ $ Earnings per share (0.92) (0.92)

COMPANY NEWS

Results for 'Transition Therapeutics Inc.' from past 30 days: No hits. (Links are to articles.)